Regeneron Pharmaceuticals is trading 5.4% up at $733.00 after reporting second-quarter financial results that significantly exceeded analyst expectations.
- Revenue rose 17% year-over-year to $4.3 billion, driven by robust performance from core products Dupixent and EYLEA HD.
- Both GAAP and non-GAAP EPS significantly beat forecasts, reflecting strong product momentum and operational execution despite broader macroeconomic noise.